Using Excipients With Biologics - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Using Excipients With Biologics


Pharmaceutical Technology Europe
Volume 23, Issue 1

Ongoing developments

Biologic manufacturers are not really reluctant to use excipients; instead, they are more wary about selecting the right partner with whom to develop the most efficient formulation with reduced frequency administration.

The ideal biomolecule delivery system should improve upon the conventional dosage form. Because of the large sizes of the biomolecules under development, the invasive routes of administration, such as systemic or subcutaneous injections, will remain the most efficient ones. We do, however, believe there is a greater role to be played by very inert excipients acting as simple bulk carriers, such carbohydrates and polyols. Mannitol is well known for its cryoprotective properties and is used for protein's lyophilisation. In fact, one very recent patent emphasises the use of polyols as stabilising factors for highly concentrated antibody liquid formulations for subcutaneous administration.4 This interest in polyols is a result of their ability to prevent aggregation of proteins in solution and to provide a viscosity compatible with subcutaneous administration.

We also advise using the latest advances in sustained release excipients to modulate the release of the biomolecule. As mentioned earlier, polymer matrix-based sustained release formulations are of interest for injectable protein lifecycle improvement.

One particular trend in the field of particle engineering technologies is in the development of solutions that would allow biologicals to be administered in standard solid dosage forms.

Dry emulsion formulations can incorporate soluble protein and provides them protection against degradation when in contact with biological fluids.5 This dry emulsion can be directly compressed as a tablet6 or can first be adsorbed onto a powder with high specific surface area for better compressibility.7

As discussed earlier, the key challenges for biologics delivery include stability and achieving the desired targeting once the biomolecules are in the body. As a supplier, we think in terms of designing excipients for specific dosage forms that can be delivered through a specific route of administration.

Most biologics are formulated for delivery via injection. This requires very strict standards for manufacturing endotoxin-free excipients. More recently, studies have been conducted regarding the development of non invasive oral delivery systems for peptides using lipids and film coating technologies for better protection and more precise targeting.1,2,5,6

Overall, we believe that it is important to continue developing innovative excipient technologies that prolong the lifecycle of biologics inside the body and, consequently, improve their delivery.

References

1. L.R. Brown, Expert Opin. Drug Deliv. 2(1) 2005.

2. M.A. Karsdal, et al., Clin. Pharmacol., 50(7) 2010.

3. B. Yu, et al. The AAPS Journal, 11(1) (2009).

4. Stable high protein concentration formulations of human anti TNF alpha antibodies. Patent US2010278822A1.

5. J. Shaji and V. Patole. Indian J Pharm Sci., 70(3) 2008.

6. E. Toorisaka, et al., J. Control. Release, 107(1) 2005.

7. R.P. Dixit and M.S. Nagarsenken, Pharm. Dev. Technol., 12(5) 2007.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
24%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
10%
All of the above.
44%
No government involvement in patient treatment or drug development.
10%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology Europe,
Click here